Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)
Phase: N/A
Priority: Normal
Start: 03/07/24
End: 09/04/24
Due: 09/04/25
Phase: N/A
Priority: Normal
Start: 07/01/25
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab) | NCT06331884 | 4TEEN4 Pharmaceuticals GmbH | user2@example.com | None | 2024-03-07 | 2024-09-04 | 2025-09-04 | - | - | 2025-07-14 |
| Procizumab (PCZ; AK1967) in Critical Cardiovascular Care | NCT06832722 | 4TEEN4 Pharmaceuticals GmbH | user2@example.com | None | 2025-07-01 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |